Blaustein Marc's Form 4 filing
Finch Therapeutics Group, Inc. (FNCH) · filed Feb 23, 2023
- Accession no.
- 0000899243-23-005985
- Filed
- Feb 23, 2023, 4:05 PM ET
- Trade date
- Feb 21, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.76K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Blaustein MarcCIK 0001880032 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2023 | Common Stock | SSaleDisposed | −4,619 | $0.38F2 | −$1,755.22 | 27,995 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average price of shares sold by the broker on behalf of certain employees of the company on February 21, 2023. The broker sold, in the aggregate on behalf of such employees, 21,651 shares in transactions ranging from $0.36 to $0.39 with a weighted average price of $0.38. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.